Description du projet DEENESFRITPL Administration intracellulaire de médicaments basée sur les nanotechnologies pour cibler Mycobacterium tuberculosis La tuberculose est un problème majeur de santé publique au niveau mondial, avec une augmentation alarmante des cas de multirésistance. La tuberculose est causée par Mycobacterium tuberculosis qui peut survivre à l’intérieur des cellules hôtes, principalement dans les macrophages. L’élimination intracellulaire de ces bactéries est plus efficace avec l’administration de produits thérapeutiques dirigés vers les cellules hôtes. Le projet TBNANO, financé par l’UE, vise à développer et à évaluer des nanocapsules chargées de médicaments antituberculeux capables de cibler les molécules des cellules hôtes. La surface des nanocapsules sera fonctionnalisée avec des peptides ciblant les macrophages et des dérivés du mannose. Cet apport de médicaments basé sur les nanotechnologies améliorera l’absorption cellulaire par les macrophages hôtes, ce qui permettra de cibler efficacement les mycobactéries intracellulaires, tout en réduisant les effets secondaires indésirables des médicaments. Afficher les objectifs du projet Masquer les objectifs du projet Objectif Tuberculosis (TB) is still a major public health problem worldwide. It is estimated that more than one-quarter of the world's population is infected with this airborne infectious disease. Moreover, the increase of multidrug- and extensively drug-resistant TB is alarming. TB is caused by Mycobacterium tuberculosis, an intracellular pathogen that can survive in host cells, mainly in macrophages. The uptake of the antitubercular drugs by infected host cells is limited. The orally or intravenously administered drugs are distributed throughout the body causing side effects and the majority of the drug molecules do not reach their targets. The elimination of the intracellular bacteria could be more efficient with host cell directed delivery. The TBNANO project aims to develop and in vitro evaluate antitubercular agent-loaded nanocapsules decorated with host cell targeting molecules. For this purpose, naturally occurring, biocompatible and biodegradable polysaccharide nanocapsules loaded with a recently approved anti-TB drug (bedaquiline) and antimicrobial peptides will be used. The surface of the nanocapsules will be functionalized with macrophage targeting ligands, such as peptides and mannose derivatives. With such nanotechnology-based drug delivery system, enhanced cellular uptake can be achieved by the host cell macrophages, therefore, the anti-TB agent can reach the intracellular bacteria as site of action. This approach leads to increased bioavailability and selectivity of the drugs while reducing their undesirable side effects. The proposed project could provide a breakthrough step in nanotechnology-based TB treatment to get closer to a world free of TB. Furthermore, this multidisciplinary project provide valuable transfer of knowledge to the host institution, as well as advanced training of the young researcher in the field of nanomaterial science to broaden her expertise in drug delivery systems. Champ scientifique medical and health scienceshealth sciencespublic healthnatural sciencesbiological sciencesmicrobiologybacteriologymedical and health scienceshealth sciencesinfectious diseasesmedical and health sciencesclinical medicinepneumologytuberculosisnatural sciencesbiological sciencesbiochemistrybiomoleculescarbohydrates Programme(s) H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions Main Programme H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility Thème(s) MSCA-IF-2018 - Individual Fellowships Appel à propositions H2020-MSCA-IF-2018 Voir d’autres projets de cet appel Régime de financement MSCA-IF-EF-ST - Standard EF Coordinateur AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS Contribution nette de l'UE € 172 932,48 Adresse CALLE SERRANO 117 28006 Madrid Espagne Voir sur la carte Région Comunidad de Madrid Comunidad de Madrid Madrid Type d’activité Research Organisations Liens Contacter l’organisation Opens in new window Site web Opens in new window Participation aux programmes de R&I de l'UE Opens in new window Réseau de collaboration HORIZON Opens in new window Coût total € 172 932,48
